Pharma

Your Article Summary

See Latest Articles

Allos Therapeutics Announces U.S. Availability of FOLOTYN(TM) (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma
Allos Therapeutics, 10/06/09

Allos Therapeutics, Inc. announced that FOLOTYN™ is now available for commercial sale in the United States. The U.S. Food and Drug Administration granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T–cell lymphoma on September 2009. This indication is based on overall response rate.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09

Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09

AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09

 See all of Drug/Product Approvals

Today in Medical Devices/Products...keeping you current

Receive free subspecialty "5-minute updates" via email

Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09

Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09

Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09

 See all of Medical Devices/Products